Michael Makris on Rising Malignancy Concerns After Hemophilia Gene Therapy: Key Challenges Highlighted in NEJM
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, posted on LinkedIn:
”There is an interesting discussion about the issue of malignancy in persons with haemophilia who have had gene therapy in the New England Journal this week.
The number of malignancies is increasing as more patients undergo gene therapy.
The key issues are:
a) Need for a standardised set of investigations
b) Need for advice on what tissue sample to collect and how to store them, to allow for the more specialised investigations
c) The interpretation of the results
d) Payment for these very expensive investigations. Manufacturers have funded these so far because most of the cases were seen in the clinical trials, but will they continue to fund it long term? ”
Stay updated with Hemostasis Today.
-
Feb 2, 2026, 17:54Danny Gaskin: Nominations are Open for the BBTS Transfusion Practitioner Special Interest Group Award 2026
-
Feb 2, 2026, 17:44Important Webinar on Care for Patients with iTTP – ISTH
-
Feb 2, 2026, 17:21Tagreed Alkaltham: Some Risks Don’t Look Like Risks in Healthcare
-
Feb 2, 2026, 17:16Sifat Jubaira: Effect of Prolonged Tourniquet Application
-
Feb 2, 2026, 17:14Vivek Mahto: Understanding Deep Vein Thrombosis – Causes, Symptoms, and Prevention
-
Feb 2, 2026, 17:08Tareq Abadl: Heparin vs Warfarin
-
Feb 2, 2026, 17:07Mary Cushman: New Research on Aspirin Use in Pregnancy and Stroke Risk in Offspring
-
Feb 2, 2026, 16:52Aravind Palraj: Young Stroke is Never Just Stroke
-
Feb 2, 2026, 16:48Seyed Mohsen Jahromi Moghadam: Antithrombotic Therapy After Transcatheter Structural Heart Interventions